LEK Pharmaceuticals D D Pharmaceutical Import Profile — Slovenia (DGFT 2022–2026)

Name: LEK Pharmaceuticals D D Pharmaceutical Import Records from India — 2 Products, $464.6K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

LEK Pharmaceuticals D D — Pharmaceutical Importer Profile (2026) | 2 Products, $464.6K Trade | TransData Nexus

LEK Pharmaceuticals D D

Pharmaceutical Importer · Slovenia · Advanced Oncology Focus · $464.6K Total Trade · DGFT Verified

LEK Pharmaceuticals D D is a pharmaceutical importer based in Slovenia with a total trade value of $464.6K across 2 products in 1 therapeutic categories. Based on 81 verified import shipments from Indian Customs (DGFT) records, LEK Pharmaceuticals D D is the #1 buyer in 1 product including Lenvatinib. LEK Pharmaceuticals D D sources from 2 verified Indian suppliers, with Sandoz Private Limited accounting for 98.1% of imports.

LEK Pharmaceuticals D D — Import Portfolio & Supplier Network

LEK Pharmaceuticals D D import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to LEK Pharmaceuticals D D?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Sandoz Private Limited	$3.5M	260	98.1%
Batavia Exports International Llp	$68.3K	12	1.9%

LEK Pharmaceuticals D D sources from 2 verified Indian suppliers across 100 distinct formulations. The sourcing is — Sandoz Private Limited accounts for 98.1% of total imports, indicating a strategic single-source relationship.

What Formulations Does LEK Pharmaceuticals D D Import?

Formulation	Value	Ships
Material no - 44100520 apixaban sdz 5mg56fct	$617.9K	16
Material no. - 44100520 apixaban sdz 5MG	$467.9K	12
Material no-44100520 apixaban sdz 5MG 56fct	$408.0K	21
Material no - 44100531 apixaban sdz 2.5MG 60fct	$363.4K	14
Material no: 44100520 apixaban sdz 5MG	$348.6K	18
Material no. - 44100462 apixaban sdz 5MG	$278.9K	9
Material no.-44100520 apixaban sdz 5MG	$117.7K	5
Material no: 44100531 apixaban sdz 2.5MG	$75.4K	7
Material no. - 44100531 apixaban sdz	$66.2K	6
Material no-44100531 apixaban sdz 2.5mg60fct	$57.9K	6
Material no: 44100462 apixaban sdz 5MG	$55.1K	2
Material no - 44104387 apixaban sdz 2.5MG 60fct	$50.0K	1
Material no - 44104426 apixaban sdz 5mg60fct	$50.0K	1
Material no - 44100521 apixaban sdz 5mg28fct	$49.0K	6
Lekadol forte 1000MG TAB paracetamol	$47.5K	4

LEK Pharmaceuticals D D imports 100 distinct pharmaceutical formulations. Showing top 15 by value. For full formulation-level data, contact TransData Nexus.

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Lenvatinib	Advanced Oncology	$304.8K	31	11.9%	1
2	Olaparib	Advanced Oncology	$159.9K	50	17.3%	2

LEK Pharmaceuticals D D imports 2 pharmaceutical products across 1 categories into Slovenia totaling $464.6K. The company is the #1 buyer for 1 product: Lenvatinib.

LEK Pharmaceuticals D D — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Lek Pharmaceuticals d.d., commonly known as Lek, is Slovenia's first and oldest pharmaceutical company, established in 1946. Headquartered at Verovškova ulica 57, 1526 Ljubljana, Slovenia, Lek specializes in the development, production, and distribution of generic pharmaceuticals, biosimilars, and active pharmaceutical ingredients. As a subsidiary of Sandoz, the generic division of Novartis, Lek plays a pivotal role in the global pharmaceutical industry, supplying medicines to nearly 60 markets worldwide.

Lek's extensive product portfolio includes antibiotics, pain relief medications, probiotics, and dietary supplements. The company is recognized as a pioneer in the field of biosimilars and is the second-largest generic pharmaceutical company globally. In Slovenia, Lek contributes approximately 2.2% to the national GDP, underscoring its significant impact on the country's economy.

2Distribution Network

Lek Pharmaceuticals d.d. operates a comprehensive distribution network to ensure the efficient delivery of its products both domestically and internationally. While specific warehouse locations and logistics capabilities are not publicly detailed, Lek's extensive reach across nearly 60 markets indicates a robust infrastructure capable of supporting global distribution. The company's strategic partnerships and affiliations, particularly with Sandoz, further enhance its logistical capabilities, facilitating the timely and reliable delivery of pharmaceutical products.

3Industry Role

In Slovenia's pharmaceutical supply chain, Lek Pharmaceuticals d.d. serves as a primary wholesaler and distributor. Its extensive product range and manufacturing capabilities position it as a key player in the Slovenian market, supplying a significant portion of the country's pharmaceutical needs. Lek's role extends beyond distribution, encompassing the development and production of a wide array of pharmaceutical products, thereby contributing to the overall stability and growth of Slovenia's healthcare sector.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — LEK Pharmaceuticals D D

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Lek Pharmaceuticals d.d. demonstrates a high degree of sourcing concentration, with a total import value of $465,000 USD from India across 81 shipments. The top two imported products are Lenvatinib ($305,000 USD, 11.9% share) and Olaparib ($160,000 USD, 17.3% share), both within the Advanced Oncology therapeutic category. This concentration indicates a strategic focus on oncology treatments, aligning with global trends emphasizing cancer care. The reliance on a limited number of suppliers—Sandoz Private Limited and Batavia Exports International LLP—suggests a stable and possibly exclusive relationship, which can lead to favorable terms and consistent product quality. However, such dependency also poses risks related to supply chain disruptions or changes in supplier dynamics.

2Supply Chain Resilience

Lek Pharmaceuticals d.d.'s supply chain resilience is bolstered by its affiliation with Sandoz, a global leader in generics and biosimilars. This partnership likely provides access to a diversified supplier base and advanced manufacturing capabilities, enhancing supply chain stability. The importation of 100 unique formulations indicates a broad product range, reducing dependency on single-source suppliers. While the primary suppliers are Sandoz Private Limited and Batavia Exports International LLP, the association with Sandoz suggests potential access to additional backup suppliers, further strengthening the supply chain's resilience.

Importing Pharmaceuticals into Slovenia — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Slovenia

1Regulatory Authority & Framework

In Slovenia, the Agency for Medicinal Products and Medical Devices (JAZMP) is the primary regulatory authority overseeing the pharmaceutical sector. The importation of medicinal products is governed by the Medicinal Products Act and the Rules on the Manufacture, Wholesale Distribution, and Import of Active Substances. These regulations ensure that imported pharmaceuticals meet the required safety, efficacy, and quality standards. For Indian generics to be marketed in Slovenia, they must undergo a marketing authorization process, which includes demonstrating compliance with EU Good Manufacturing Practice (GMP) standards and obtaining approval from JAZMP. (jazmp.si)

2Import Licensing & GMP

Import licensing in Slovenia requires that entities hold a manufacturing authorization for medicinal products, which also covers import activities. This authorization is granted by JAZMP and ensures that imported pharmaceuticals adhere to EU GMP standards. Indian exporters aiming to supply Lek Pharmaceuticals d.d. must ensure their manufacturing facilities are certified under EU GMP or recognized by the World Health Organization (WHO) GMP standards. Additionally, obtaining a wholesale distribution authorization is necessary for the legal distribution of medicinal products within Slovenia. (jazmp.si)

LEK Pharmaceuticals D D — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Lek Pharmaceuticals d.d.'s focus on Advanced Oncology products, particularly Lenvatinib and Olaparib, aligns with the increasing global demand for cancer treatments. This strategic emphasis allows Lek to address critical therapeutic areas and cater to a significant patient population. The decision to import these specific products is likely driven by market demand, the availability of effective generics, and the company's expertise in biosimilars and complex generics.

2Sourcing Profile

Lek Pharmaceuticals d.d. employs a sourcing strategy that prioritizes high-quality generics and biosimilars, with a particular focus on oncology treatments. The company's partnership with Sandoz facilitates access to a diverse range of formulations and advanced manufacturing technologies. India's robust pharmaceutical manufacturing sector, with its adherence to international quality standards, makes it a key supplier for Lek's procurement needs.

3Market Positioning

Lek Pharmaceuticals d.d. serves a broad segment of the Slovenian pharmaceutical market, including retail pharmacies, hospitals, and government tenders. Its extensive product portfolio and distribution capabilities enable it to meet the diverse needs of the healthcare sector, positioning Lek as a comprehensive supplier of pharmaceutical products in Slovenia.

Seller's Guide — How to Become a Supplier to LEK Pharmaceuticals D D

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to collaborate with Lek Pharmaceuticals d.d., particularly in the oncology segment. However, the existing strong relationships with Sandoz Private Limited and Batavia Exports International LLP may present challenges for new entrants. To capitalize on this opportunity, Indian exporters should focus on offering high-quality products, competitive pricing, and compliance with EU regulatory standards.

2Requirements & Qualifications

Indian exporters aiming to supply Lek Pharmaceuticals d.d. must ensure their manufacturing facilities are certified under EU GMP or recognized by WHO GMP standards. They must obtain a manufacturing authorization for medicinal products, which also covers import activities, and a wholesale distribution authorization. Additionally, compliance with Slovenian labeling requirements, including Slovenian language labeling and serialization mandates, is essential.

3How to Approach

Frequently Asked Questions — LEK Pharmaceuticals D D

What products does LEK Pharmaceuticals D D import from India?

LEK Pharmaceuticals D D imports 2 pharmaceutical products across 1 categories. Top imports: Lenvatinib ($304.8K), Olaparib ($159.9K).

Who supplies pharmaceuticals to LEK Pharmaceuticals D D from India?

LEK Pharmaceuticals D D sources from 2 verified Indian suppliers. The primary supplier is Sandoz Private Limited (98.1% of imports, $3.5M).

What is LEK Pharmaceuticals D D's total pharmaceutical import value?

LEK Pharmaceuticals D D's total pharmaceutical import value from India is $464.6K, based on 81 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does LEK Pharmaceuticals D D focus on?

LEK Pharmaceuticals D D imports across 1 categories. The largest: Advanced Oncology (100.0%).

Get Full LEK Pharmaceuticals D D Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.